IP Library Granted Patent US 8,114,894
Granted Patent B2
US 8,114,894 · App. 12/630,468 · Granted Feb 14, 2012

Bicyclic compounds and methods of making and using same

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,114,894
App. No.
12/630,468
Granted
Feb 14, 2012
Kind
B2
Abstract

Disclosed herein are compounds that may be modulators of 5-HT receptors, and methods of making and using same.

Claims (131)

1. A compound of formula II:

or pharmaceutically acceptable salts or N-oxides thereof, wherein

R 1 is, independently for each occurrence, selected from halogen, hydroxyl, C 1 -C 6 alkyl, C 1 -C 6 haloalkyl, C 3 -C 6 cycloalkyl, C 1 -C 6 alkoxy, nitro, cyano, amino, sulfonyl, C 1 -C 6 alkylsulfonyl, sulfamoyl, carbamoyl, carboxyl, N—C 1 -C 6 alkylsulfamoyl, and N—C 1 -C 6 alkylcarbamoyl;

B is selected from formulae IIA and IIB:

R 2 is selected from C 1 -C 6 alkyl and C 3 -C 6 cycloalkyl, wherein R 2 may be optionally substituted with one, two, or three substituents selected, independently for each occurrence, from halogen, alkoxy, nitro, cyano, amino, and carboxyl;

R 3 and R 4 are each independently selected from hydrogen, C 1 -C 6 alkoxy, C 1 -C 6 alkyl, aryl, C 3 -C 6 cycloalkyl, halogen, heteroaryl, heterocyclyl, and hydroxyl, wherein R 3 or R 4 , if not hydrogen, may be optionally substituted by one, two, or three substituents represented by R 10 , or R 3 and R 4 are taken together with the carbon atom to which they are attached to form a four, five, or six membered heterocyclyl or C 3 -C 6 cycloalkyl optionally substituted by one, two, or three substituents each represented by R 10 ;

R 7 is selected from C 1 -C 6 alkoxy, C 1 -C 6 alkyl, cyano, halogen, hydrogen, and hydroxyl;

R 8 is selected from hydrogen and alkyl optionally substituted by one, two, or three substituents each selected from halogen, hydroxyl, C 1 -C 6 alkylsulfonyl, C 1 -C 6 alkoxy, N—C 1 -C 6 alkylamino, N,N-diC 1 -C 6 alkylamino, cyano, carboxyl, sulfonamido, and C 1 -C 6 alkylsulfonamido;

R 9 is, independently for each occurrence, selected from hydrogen, halogen, hydroxyl, nitro, cyano, amino, sulfonyl, C 1 -C 6 alkylsulfonyl, sulfamoyl, sulfonamido, C 1 -C 6 alkylsulfonamido, carbamoyl, carboxyl, N—C 1 -C 6 alkylsulfamoyl, and N—C 1 -C 6 alkylcarbamoyl, C 1 -C 6 alkyl, C 3 -C 6 cycloalkyl, C 1 -C 6 alkylthio, and C 1 -C 6 alkoxy, wherein the alkyl, cycloalkyl or alkoxy is optionally substituted by one, two, or three substituents independently selected from halogen, hydroxyl, carboxy, cyano, amido, nitro, and amino;

R 10 is, independently for each occurrence, selected from halogen, hydroxyl, nitro, cyano, amino, sulfonyl, C 1 -C 6 alkylsulfonyl, sulfamoyl, sulfonamido, C 1 -C 6 alkylsulfonamido, carbamoyl, carboxyl, N—C 1 -C 6 alkylsulfamoyl, and N—C 1 -C 6 alkylcarbamoyl, C 1 -C 6 alkyl, C 3 -C 6 cycloalkyl, C 1 -C 6 alkylthio, and C 1 -C 6 alkoxy, wherein the alkyl, cycloalkyl or alkoxy is optionally substituted by one, two, or three substituents independently selected from halogen, hydroxyl, carboxy, cyano, amido, nitro, and amino; and

m is 0, 1, 2, 3, or 4.

2. A compound selected from:

2-(1-isopropyl-1H-indol-3-yl)-2-oxo-N-(3-(piperidin-1-yl)propyl)acetamide;

2-(1-isopropyl-1H-indol-3-yl)-2-oxo-N-(2-(piperidin-1-yl)ethyl)acetamide;

N-(2-(diethylamino)ethyl)-2-(1-isopropyl-1H-indol-3-yl)-2-oxoacetamide;

2-(1-ethyl-1H-indol-3-yl)-2-oxo-N-(2-(piperidin-1-yl)ethyl)acetamide;

2-(1-sec-butyl-1H-indol-3-yl)-2-oxo-N-(2-(piperidin-1-yl)ethyl)acetamide;

2-(5-chloro-1-isopropyl-1H-indol-3-yl)-2-oxo-N-(2-(piperidin-1-yl)ethyl)acetamide;

2-(1-isopropyl-6-nitro-1H-indol-3-yl)-2-oxo-N-(2-(piperidin-1-yl)ethyl)acetamide;

2-(6-amino-1-isopropyl-1H-indol-3-yl)-2-oxo-N-(2-(piperidin-1-yl)ethyl)acetamide;

2-(6-amino-7-chloro-1-isopropyl-1H-indol-3-yl)-2-oxo-N-(2-(piperidin-1-yl)ethyl)acetamide;

2-(1-isopropyl-1H-indol-3-yl)-2-oxo-N-(2-(pyrrolidin-1-yl)ethyl)acetamide;

2-(1-isopropyl-5-methoxy-1H-indol-3-yl)-2-oxo-N-(2-(piperidin-1-yl)ethyl)acetamide;

2-(1-isopropyl-5-methyl-1H-indol-3-yl)-2-oxo-N-(2-(piperidin-1-yl)ethyl)acetamide;

N-(1-(3-hydroxypropyl)piperidin-4-yl)-2-(1-isopropyl-1H-indol-3-yl)-2-oxoacetamide;

2-(1-isopropyl-1H-indol-3-yl)-2-oxo-N-(1-propylpiperidin-4-yl)acetamide;

N-((1-isobutylpiperidin-4-yl)methyl)-2-(1-isopropyl-1H-indol-3-yl)-2-oxoacetamide;

2-(1-isopropyl-1H-indol-3-yl)-2-oxo-N-(2(4-(trifluoromethyl)piperidin-1-yl)ethyl)acetamide;

N-(1-butylpiperidin-4-yl)-2-(1-isopropyl-1H-indol-3-yl)-2-oxoacetamide;

2-(1-isopropyl-1H-indol-3-yl)-N-(1-(3-methoxypropyl)piperidin-4-yl)-2-oxoacetamide;

2-(1-isopropyl-1H-pyrrolo[2,3-b]pyridin-3-yl)-2-oxo-N-(2-(piperidin-1-yl)ethyl)acetamide;

2-(1-isopropyl-1H-indol-3-yl)-N-(1-(2-(methylsulfonamido)ethyl)piperidin-4-yl)-2-oxoacetamide;

2-(1-isopropyl-1H-indol-3-yl)-2-oxo-N-(2-(4-propylpiperidin-1-yl)ethyl)acetamide;

N-(2-(4-(2-hydroxyethyl)piperidin-1-yl)ethyl)-2-(1-isopropyl-1H-indol-3-yl)-2-oxoacetamide;

N-(2-(4-ethylpiperidin-1-yl)ethyl)-2-(1-isopropyl-1H-indol-3-yl)-2-oxoacetamide; and

N-(2-(4-butylpiperidin-1-yl)ethyl)-2-(1-isopropyl-1H-indol-3-yl)-2-oxoacetamide,

or a pharmaceutically acceptable salt or N-oxide thereof.

3. A compound selected from:

2-(1-ethyl-1H-indol-3-yl)-2-oxo-N-(3-(piperidin-1-yl)propyl)acetamide;

N-(2-(ethyl(methyl)amino)ethyl)-2-(1-isopropyl-1H-indol-3-yl)-2-oxoacetamide;

2-(1-sec-butyl-1H-indol-3-yl)-2-oxo-N-(3-(piperidin-1-yl)propyl)acetamide;

2-(1-isobutyl-1H-indol-3-yl)-2-oxo-N-(3-(piperidin-1-yl)propyl)acetamide;

2-(1-isopropyl-1H-indol-3-yl)-2-oxo-N-(3-(pyrrolidin-1-yl)propyl)acetamide;

N-(3-(ethyl(methyl)amino)propyl)-2-(1-isopropyl-1H-indol-3-yl)-2-oxoacetamide;

2-(1-isobutyl-1H-indol-3-yl)-2-oxo-N-(2-(piperidin-1-yl)ethyl)acetamide;

2-(1-isopropyl-1H-indol-3-yl)-2-oxo-N-(2-(pyrrolidin-1-yl)ethyl)acetamide;

(R)-2-(1-sec-butyl-1H-indol-3-yl)-2-oxo-N-(3-(piperidin-1-yl)propyl)acetamide;

(S)-2-(1-sec-butyl-1H-indol-3-yl)-2-oxo-N-(3-(piperidin-1-yl)propyl)acetamide;

(S)-2-(1-sec-butyl-1H-indol-3-yl)-2-oxo-N-(2-(piperidin-1-yl)ethyl)acetamide;

(R)-2-(1-sec-butyl-1H-indol-3-yl)-2-oxo-N-(2-(piperidin-1-yl)ethyl)acetamide;

2-(4-hydroxy-1-isopropyl-1H-indol-3-yl)-2-oxo-N-(3-(piperidin-1-yl)propyl)acetamide;

2-(4-hydroxy-1-isopropyl-1H-indol-3-yl)-2-oxo-N-(2-(piperidin-1-yl)ethyl)acetamide;

2-(1-ethyl-4-hydroxy-1H-indol-3-yl)-2-oxo-N-(2-(piperidin-1-yl)ethyl)acetamide;

2-(6-amino-1-isopropyl-1H-indol-3-yl)-2-oxo-N-(3-(piperidin-1-yl)propyl)acetamide;

2-(5-amino-6-chloro-1-isopropyl-1H-indol-3-yl)-2-oxo-N-(3-(piperidin-1-yl)propyl)acetamide;

2-(6-amino-5-chloro-1-isopropyl-1H-indol-3-yl)-2-oxo-N-(2-(piperidin-1-yl)ethyl)acetamide;

2-(5-amino-6-chloro-1-isopropyl-1H-indol-3-yl)-2-oxo-N-(2-(piperidin-1-yl)ethyl)acetamide;

2-(1-isopropyl-1H-indol-3-yl)-N-(2-(4-methylpiperidin-1-yl)ethyl)-2-oxoacetamide;

2-(1-isopropyl-1H-pyrrolo[2,3-c]pyridin-3-yl)-2-oxo-N-(2-(piperidin-1-yl)ethyl)acetamide;

2-(1-isopropyl-1H-pyrrolo[3,2-b]pyridin-3-yl)-2-oxo-N-(2-(piperidin-1-yl)ethyl)acetamide;

2-(1-isopropyl-1H-pyrrolo[3,2-c]pyridin-3-yl)-2-oxo-N-(2-(piperidin-1-yl)ethyl)acetamide;

2-(4-isopropyl-4H-thieno[3,2-b]pyrrol-6-yl)-2-oxo-N-(2-(piperidin-1-yl)ethyl)acetamide;

2-(1-isopropyl-2-methyl-1H-indol-3-yl)-2-oxo-N-(2-(piperidin-1-yl)ethyl)acetamide;

2-(2-ethyl-1-isopropyl-1H-indol-3-yl)-2-oxo-N-(2-(piperidin-1-yl)ethyl)acetamide;

2-(1-isopropyl-1H-indol-3-yl)-N-(1-morpholinopropan-2-yl)-2-oxoacetamide;

2-(1-isopropyl-1H-indol-3-yl)-2-oxo-N-((1-propylpyrrolidin-3-yl)methyl)acetamide;

N-((1-dimethylamino)cyclopentyl)methyl)-2-(1-isopropyl-1H-indol-3-yl)-2-oxoacetamide;

N-(1-ethylpiperidin-3-yl)-2-(1-isopropyl-1H-indol-3-yl)-2-oxoacetamide;

N-((1-ethylpyrrolidin-2-yl)methyl)-2-(1-isopropyl-1H-indol-3-yl)-2-oxoacetamide;

N-((4-hydroxy-1-methylpiperidin-4-yl)methyl)-2-(1-isopropyl-1H-indol-3-yl)-2-oxoacetamide;

N-(3-(dimethylamino)cyclopentyl)-2-(1-isopropyl-1H-indol-3-yl)-2-oxoacetamide;

N-(3-(dimethylamino)cyclohexyl)-2-(1-isopropyl-1H-indol-3-yl)-2-oxoacetamide;

N-(2-(3-fluoropyrrolidin-1-yl)ethyl)-2-(1-isopropyl-1H-indol-3-yl)-2-oxoacetamide;

N-(2-((2-fluoroethyl)(methyl)amino)ethyl)-2-(1-isopropyl-1H-indol-3-yl)-2-oxoacetamide;

N-(2-(4-fluoropiperidin-1-yl)ethyl)-2-(1-isopropyl-1H-indol-3-yl)-2-oxoacetamide;

N-(2-(3-hydroxypyrrolidin-1-yl)ethyl)-2-(1-isopropyl-1H-indol-3-yl)-2-oxoacetamide;

2-(1-isopropyl-1H-indol-3-yl)-N-(2-(3-(methylsulfonyl)pyrrolidin-1-yl)ethyl)-2-oxoacetamide;

N-(2-(4-ethoxypiperidin-1-yl)ethyl)-2-(1-isopropyl-1H-indol-3-yl)-2-oxoacetamide;

N-(2-(4-(dimethylamino)piperidin-1-yl)ethyl)-2-(1-isopropyl-1H-indol-3-yl)-2-oxoacetamide;

N-(2-(4-ethylpiperazin-1-yl)ethyl)-2-(1-isopropyl-1H-indol-3-yl)-2-oxoacetamide;

2-(1-isopropyl-1H-indazol-3-yl)-2-oxo-N-(2-(piperidin-1-yl)ethyl)acetamide;

2-(1-(2-hydroxyethyl)-1H-indol-3-yl)-2-oxo-N-(2-(piperidin-1-yl)ethyl)acetamide;

(R)—N-(2-(4-(2-hydroxy-3-(N-methylmethylsulfonamido)propyl)piperidin-1-yl)ethyl)-2-(1-isopropyl-1H-indol-3-yl)-2-oxoacetamide;

2-(1-isopropyl-1H-indol-3-yl)-N-(2-(4-(3-(methylsulfonyl)propyl)piperidin-1-yl)ethyl)-2-oxoacetamide;

N-(3-(diethylamino)propyl)-2-(1-isopropyl-1H-indol-3-yl)-2-oxoacetamide;

N-(4-(diethylamino)cyclohexyl)-2-(1-isopropyl-1H-indol-3-yl)-2-oxoacetamide;

N-(1-ethylpiperidin-4-yl)-2-(1-isopropyl-1H-indol-3-yl)-2-oxoacetamide;

2-(1-isopropyl-1H-indol-3-yl)-N-(3-(4-methylpiperidin-1-yl)propyl)-2-oxoacetamide;

N-(3-(4-ethylpiperidin-1-yl)propyl)-2-(1-isopropyl-1H-indol-3-yl)-2-oxoacetamide;

2-(1-isopropyl-1H-indol-3-yl)-2-oxo-N-(3-(4-propylpiperidin-1-yl)propyl)acetamide;

2-(1-isopropyl-1H-indol-3-yl)-2-oxo-N-((1-propylpiperidin-4-yl)methyl)acetamide;

N-((1-butylpiperidin-4-yl)methyl)-2-(1-isopropyl-1H-indol-3-yl)-2-oxoacetamide;

N-((4-chloro-1-methylpiperidin-4-yl)methyl)-2-(1-isopropyl-1H-indol-3-yl)-2-oxoacetamide;

N-((1,4-dimethylpiperidin-4-yl)methyl)-2-(1-isopropyl-1H-indol-3-yl)-2-oxoacetamide;

N-(2-(4-(dimethylamino)cyclohexyl)ethyl)-2-(1-isopropyl-1H-indol-3-yl)-2-oxoacetamide;

N-(2-(4-(ethylamino)cyclohexyl)ethyl)-2-(1-isopropyl-1H-indol-3-yl)-2-oxoacetamide;

N-((4-(dimethylamino)cyclohexyl)methyl)-2-(1-isopropyl-1H-indol-3-yl)-2-oxoacetamide;

N-((4-(diethylamino)cyclohexyl)methyl)-2-(1-isopropyl-1H-indol-3-yl)-2-oxoacetamide;

2-(1-isopropyl-1H-indol-3-yl)-N-(6-isopropylpiperidin-3-yl)-2-oxoacetamide;

N-(6-butylpiperidin-3-yl)-2-(1-isopropyl-1H-indol-3-yl)-2-oxoacetamide;

N-(6-(3-hydroxypropyl)piperidin-3-yl)-2-(1-isopropyl-1H-indol-3-yl)-2-oxoacetamide;

2-(1-(1-chloroethyl)-1H-indol-3-yl)-N-(2-(diethylamino)ethyl)-2-oxoacetamide;

N-(2-(diethylamino)ethyl)-2-oxo-2-(1-(2-oxopropyl)-1H-indol-3-yl)acetamide;

2-(1-(1-cyanoethyl)-1H-indol-3-yl)-N-(2-(diethylamino)ethyl)-2-oxoacetamide;

N-(2-(4-(3-hydroxypropyl)piperidin-1-yl)ethyl)-2-(1-isopropyl-1H-indol-3-yl)-2-oxoacetamide;

N-((1-(3-hydroxypropyl)piperidin-4-yl)methyl)-2-(1-isopropyl-1H-indol-3-yl)-2-oxoacetamide;

N-(1-(3-hydroxybutyl)piperidin-4-yl)-2-(1-isopropyl-1H-indol-3-yl)-2-oxoacetamide;

N-((1-ethyl-4-hydroxypiperidin-4-yl)methyl)-2-(1-isopropyl-1H-indol-3-yl)-2-oxoacetamide;

N-((4-hydroxy-1-propylpiperidin-4-yl)methyl)-2-(1-isopropyl-1H-indol-3-yl)-2-oxoacetamide;

N-((1-butyl-4-hydroxypiperidin-4-yl)methyl)-2-(1-isopropyl-1H-indol-3-yl)-2-oxoacetamide;

N,N-diethyl-4-(4-(2-(1-isopropyl-1H-indol-3-yl)-2-oxoacetamido)piperidin-1-yl)butanamide;

2-(1-isopropyl-1H-indol-3-yl)-N-(3-morpholinopropyl)-2-oxoacetamide;

2-(1-isopropyl-1H-indol-3-yl)-2-oxo-N-(4-(piperidin-1-yl)butyl)acetamide;

2-(1-isopropyl-1H-indol-3-yl)-2-oxo-N-(1-pentylpiperidin-4-yl)acetamide;

N-(1-hexylpiperidin-4-yl)-2-(1-isopropyl-1H-indol-3-yl)-2-oxoacetamide;

3-(4-(2-(1-isopropyl-1H-indol-3-yl)-2-oxoacetamido)piperidin-1-yl)-N,N-dimethylpropanamide;

2-(3-(2-oxo-2-(2-(piperidin-1-yl)ethylamino)acetyl)-1H-indol-1-yl)acetic acid;

3-(3-(2-oxo-2-(2-(piperidin-1-yl)ethylamino)acetyl)-1H-indol-1-yl)propanoic acid;

2-(3-(2-oxo-2-(2-(piperidin-1-yl)ethylamino)acetyl)-1H-indol-1-yl)propanoic acid;

1-(2-(2-(1-isopropyl-1H-indol-3-yl)-2-oxoacetamido)ethyl)piperidine-4-carboxylic acid;

N-(3-(4-(2-hydroxyethyl)piperidin-1-yl)propyl)-2-(1-isopropyl-1H-indol-3-yl)-2-oxoacetamide;

2-(1-isopropyl-1H-indol-3-yl)-N-(1-(2-methoxyethyl)piperidin-4-yl)-2-oxoacetamide;

2-(1-isopropyl-1H-indol-3-yl)-N-(2-(4-(methoxymethyl)piperidin-1-yl)ethyl)-2-oxoacetamide;

N-(2-(4-(2-hydroxypropyl)piperidin-1-yl)ethyl)-2-(1-isopropyl-1H-indol-3-yl)-2-oxoacetamide;

2-(5-fluoro-1-isopropyl-1H-indol-3-yl)-2-oxo-N-(2-(piperidin-1-yl)ethyl)acetamide;

2-(5-fluoro-1-methyl-1H-indol-3-yl)-2-oxo-N-(2-(piperidin-1-yl)ethyl)acetamide;

2-(1-methyl-1H-indol-3-yl)-2-oxo-N-(2-(piperidin-1-yl)ethyl)acetamide;

2-(1-isopropyl-1H-indol-3-yl)-N-(1-(2-(methylthio)ethyl)piperidin-4-yl)-2-oxoacctamide: and

2-(1-isopropyl-1H-indol-3-yl)-2-oxo-N-(1-(4,4,4-trifluorobutyl)piperidin-4-yl)acetamide,

or a pharmaceutically acceptable salt or N-oxide thereof.

4. A pharmaceutical composition comprising a compound, or a pharmaceutically acceptable salt or N-oxide thereof, according claim 1 and a pharmaceutically acceptable carrier.

Assignments (5)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 22, 2018
From: NANOTHERAPEUTICS INC
To: NANOSHIFT, LLC
Reel/Frame 046656/0784 →
RELEASE OF SECURITY INTEREST Recorded May 19, 2016
From: WHITE OAK GLOBAL ADVISORS, LLC AS AGENT
To: NANOTHERAPEUTICS, INC.
Reel/Frame 038651/0947 →
SECURITY INTEREST Recorded Mar 20, 2015
From: NANOTHERAPEUTICS, INC.
To: WHITE OAK GLOBAL ADVISORS, LLC
Reel/Frame 035236/0932 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 14, 2011
From: GHOSH, SHOMIR; GOLAN, GALI; INBAL, BOAZ; JACQUES, VINCENT; LOBERA, MERCEDES
To: EPIX DELAWARE, INC.
Reel/Frame 027379/0575 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 13, 2011
From: EPIX DELAWARE, INC.
To: NANOTHERAPEUTICS, INC.
Reel/Frame 027376/0548 →